Suppr超能文献

口服抗凝治疗的心房颤动患者的临床结局和跌倒史:来自 ARISTOTLE 试验的见解。

Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial.

机构信息

Cape Fear Heart Associates, New Hanover Regional Medical Center, Wilmington, NC.

University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital of Bucharest, Romania.

出版信息

Am J Med. 2018 Mar;131(3):269-275.e2. doi: 10.1016/j.amjmed.2017.10.036. Epub 2017 Nov 6.

Abstract

PURPOSE

We assessed outcomes among anticoagulated patients with atrial fibrillation and a history of falling, and whether the benefits of apixaban vs warfarin are consistent in this population.

METHODS

Of the 18,201 patients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study, 16,491 had information about history of falling-753 with history of falling and 15,738 without history of falling. The primary efficacy outcome was stroke or systemic embolism; the primary safety outcome was major bleeding.

RESULTS

When compared with patients without a history of falling, patients with a history of falling were older, more likely to be female and to have dementia, cerebrovascular disease, depression, diabetes, heart failure, osteoporosis, fractures, and higher CHADS-VASc (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or TIA or thromboembolism, Vascular disease, Age 65-74 years, Sex category female) and HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile international normalized ratio, Elderly, Drugs or alcohol) scores. Patients with a history of falling had higher rates of major bleeding (adjusted hazard ratio [HR] 1.39; 95% confidence interval [CI], 1.05-1.84; P = .020), including intracranial bleeding (adjusted HR 1.87; 95% CI, 1.02-3.43; P = .044) and death (adjusted HR 1.70; 95% CI, 1.36-2.14; P < .0001), but similar rates of stroke or systemic embolism and hemorrhagic stroke. There was no evidence of a differential effect of apixaban compared with warfarin on any outcome, regardless of history of falling. Among those with a history of falling, subdural bleeding occurred in 5 of 367 patients treated with warfarin and 0 of 386 treated with apixaban.

CONCLUSIONS

Patients with atrial fibrillation and a history of falling receiving anticoagulation have a higher risk of major bleeding, including intracranial, and death. The efficacy and safety of apixaban compared with warfarin were consistent, irrespective of history of falling.

摘要

目的

我们评估了有房颤和跌倒史的抗凝患者的结局,并评估了在该人群中,阿哌沙班相对于华法林的获益是否一致。

方法

在阿哌沙班减少房颤卒中及其他血栓栓塞事件(ARISTOTLE)研究的 18201 例患者中,有 16491 例患者有跌倒史信息,其中 753 例有跌倒史,15738 例无跌倒史。主要疗效终点为卒中或全身性栓塞;主要安全性终点为大出血。

结果

与无跌倒史的患者相比,有跌倒史的患者年龄更大,更可能为女性,且更易伴发痴呆、脑血管病、抑郁、糖尿病、心力衰竭、骨质疏松症、骨折以及更高的 CHADS-VASc(充血性心力衰竭、高血压、年龄≥75 岁、糖尿病、既往卒中或 TIA 或血栓栓塞、血管疾病、年龄 65-74 岁、性别女性)和 HAS-BLED(高血压、肾功能和肝功能异常、卒中、出血、不稳定的国际标准化比值、年龄较大、合并应用药物或酒精)评分。有跌倒史的患者大出血发生率更高(校正后的风险比[HR]1.39;95%置信区间[CI],1.05-1.84;P=0.020),包括颅内出血(校正 HR 1.87;95%CI,1.02-3.43;P=0.044)和死亡(校正 HR 1.70;95%CI,1.36-2.14;P<0.0001),但卒中或全身性栓塞和出血性卒中发生率相似。无论是否有跌倒史,阿哌沙班与华法林相比,在任何结局上均无证据表明存在差异效应。在有跌倒史的患者中,华法林组 367 例患者中有 5 例发生硬膜下出血,阿哌沙班组 386 例患者中无 1 例发生。

结论

正在接受抗凝治疗的有房颤和跌倒史的患者发生大出血(包括颅内出血)和死亡的风险更高。阿哌沙班与华法林相比,其疗效和安全性一致,与有无跌倒史无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验